IDEAYA Biosciences, Inc. (IDYA): Cash & Equivalents
$112.83M
As of 2025-12-31
$272.59M
As of 2026-06-30
+18.0%
3-year compound annual growth
+9.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $112.83M | +33.7% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $84.38M | -46.3% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $157.02M | +128.8% | 2026-02-17, Balance as of period end |
| 2022-12-31 | $68.63M | -25.4% | 2025-02-18, Balance as of period end |
| 2021-12-31 | $92.05M | +27.8% | 2024-02-20, Balance as of period end |
| 2020-12-31 | $72.04M | +111.5% | 2023-03-07, Balance as of period end |
| 2019-12-31 | $34.07M | +66.1% | 2022-03-18, Balance as of period end |
| 2018-12-31 | $20.50M | +244.0% | 2021-03-23, Balance as of period end |
| 2017-12-31 | $5.96M | n/a | 2020-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $112.83M | +33.7% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $29.64M | -57.2% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $238.20M | +93.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $184.84M | +256.4% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $222.00M | +48.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
Compare IDYA, VNDA, AMRN, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗